Charité – Universitätsmedizin Berlin at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Charité – Universitätsmedizin Berlin brings 8 presentations to ASH 2026 in New Orleans. Its program spans leukemia, lymphoma and myeloma, with a focus on transplant outcomes. Research covers CRISPR screens for myeloma drug resistance and a chemotherapy-free first-line lymphoma trial.
| Organization | ASH 2026 Attendance |
|---|---|
Charité – Universitätsmedizin Berlin Berlin, Germany | |
University hospital and joint medical faculty of Berlin's Free and Humboldt universities, one of Europe's largest. | Talk Sat Dec 12 2:00pm–3:15pm AML Immune Escape Mechanisms Driving Post-Therapy Relapse Why acute myeloid leukemia returns after chemotherapy, donor transplant, or immunotherapy, traced to leukemia evolution and exhausted T cells in the marrow. Oral Sun Dec 13 12:00pm–1:30pm Oral Sun Dec 13 4:30pm–6:00pm Poster Sun Dec 13 6:00pm–8:00pm Oral Mon Dec 14 4:30pm–6:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm |
Find decision makers at Charité – Universitätsmedizin Berlin
Tell us what you sell and we’ll find the people at Charité – Universitätsmedizin Berlin most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction